# Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

> **NCT04688008** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Bioavailability Study

## Interventions

- **DRUG:** Hetrombopag

## Key facts

- **NCT ID:** NCT04688008
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-18
- **Primary completion:** 2020-10-12
- **Final completion:** 2020-10-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688008, "Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04688008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*